www.infystocks.co.uk

6 January 2007

Biocon

2002-Biocon India appointed DSP Merrill Lynch and Kotak Mahindra for its Rs 150-crore IPO scheduled for June next year. Biocon-Shantha Biotech, the 50:50 joint venture between Biocon India and Shantha Biotechnics, focuses on the domestic and global human insulin markets by maximizing on R&D manufacturing and regulatory capacities of the two companies.

2003

-ICICI Venture offloads 10-pc stake in Biocon

2004

-Clinigene International inaugurates human pharmacology unit for clinical trials

-Comes out with an Initial Public Offering (IPO) of 10 million shares at a price of Rs 315 per share for a face value of Rs 5 per share which constitutes 10% of the post-issue capital (Rs 100 crore), listed at Rs 425

-Biocon Ltd has entered into a nine-year export contract with US major Bristol-Myers Squibb Co to supply the bulk form of its recombinant human insulin

-Biocon forays into lifestyle drugs market

-Biocon's clinical research arm, Clinigene International Pvt Ltd. re-accredited by the College of American Pathologists (CAP) following a recent inspection

-Biocon Ltd has informed that in an unusual commercial transaction between Cuba and USA, a Californian Biotechnology Company, CancerVax Corporation received a rare US Government approval to License three experimental cancer drugs from a leading Cuban Institute (CIMAB)

-Biocon said on July 26 that its Cuban partner CIMAB (Centre for Molecular Immunology) in the joint venture with Biocon Biopharmaceuticals will be able to license out three experimental cancer drugs to a Californian Biotechnology company, CancerVax Corporation

-Biocon, Syngene enters into Research Agreement with Novartis Institutes for Biomedical Research Inc

-Biocon unveils new bio insulin

2005

Biocon signs MoU with Karolinska Institute.

-Ms Kiran Mazumdar-Shaw, CMD of Biocon Ltd, has been honoured with the Corporate Leadership Award 2005 of the American India Foundation (AIF)

-Biocon signs Licensing agreement with Bentley Pharmaceuticals Inc.

2006

-Biocon ties up with ICICI Prudential Life Insurance

-Biocon concludes Phase-IV trials of Insugem

Biocon Ltd has announced the Company and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of Bio-pharmaceuticals for the GCC countries (Gulf Cooperation Council).
This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.
Dr Kiran Mazumdar-Shaw, Chairman and Managing Director, of the Company said, "The GCC region is an important market for Biocon and the JV with Neopharma is an important milestone for Biocon's global foray. Neopharma has established a world class manufacturing facility for finished formulations which was inaugurated by President APJ Abdul Kalam in 2003".
The JV will leverage the leadership position that Neopharma commands in the region under the leadership of Dr B R Shetty and expand Neopharma's existing portfolio with a range of the Company's generic and novel therapeutics that encompass Diabetes, CVS, Oncology, Auto-immune and Immunosuppressive drugs.

THE STOCK is not running from lasyt 2 year many funds and trraders and fill lo0king this counter with full opf confidence one can must have delivery of biocon one can get 50 to 60% grouth in this fyo7

by erectusplus at 11:55:00 |